CyberKnife® for Prostate Cancer

CyberKnife® is a noninvasive way to treat prostate cancer in five treatments or less.

The CyberKnife® System is a robotic system designed to deliver high-precision radiation therapy to the prostate. Unlike other radiation treatments, the CyberKnife® System continually tracks and automatically corrects the radiation beam for movement of the prostate in real time. This motion tracking and adjustment enhances the doctor’s ability to target the tumor and preserve healthy tissue.

In most cases, radiosurgery with the CyberKnife® System for prostate cancer does not require a catheter. Traditional prostate cancer surgery requires the use of a catheter for help with urination, for up to 2 weeks post-procedure.

Advantages of CyberKnife® for Prostate Cancer

  • With CyberKnife® radiosurgery for prostate cancer, the majority of patients can continue normal activity during and immediately following treatment. With traditional prostate cancer surgery, patients must limit normal activity for 3-5 weeks.
  • In a recent clinical study of patients treated with CyberKnife® radiosurgery for prostate cancer, the majority of these patients maintained sexual function.
  • Patients treated with the CyberKnife® System for prostate cancer reported a return to normal urinary and bowel function by 6 months post-procedure.1
  • Prostate cancer treatment with the CyberKnife® System is completed in 4-5 treatment sessions, over the course of a week. Conventional radiation therapy typically requires 30-40 treatment sessions, over the course of several weeks.
  • The CyberKnife® System delivers the required radiation dose to the prostate with pinpoint precision, thereby minimizing the radiation that is delivered to the bowel and urinary tract.

This video is used with permission from Accuray Incorporated.

King et al. International Journal of Radiation Oncology.2013. Health-Related Quality of Life After Sterotactic Body Radiation Therapy for Localized Prostate Cancer: Results from a Multi-institutional Consortium of Prospective Trials